Novo Nordisk's Weight-Loss Pill Continues to Impress -- Market Talk

Dow Jones03-23

1102 GMT - Novo Nordisk's Wegovy weight-loss pill launch continues to impress, UBS analyst Matthew Weston writes. Latest data show there were 89,279 total prescriptions for the Wegovy pill in its tenth week of launch, up 10% on the week, UBS says. There is also no material evidence that the pill is taking market share from the injectable market, it adds. The bank says sales volumes have risen due to the lower price point compared with the Wegovy injection, which is a positive as the company's guidance assumed more limited volume growth for the injectable product amid competition from the pill. Focus points later in the year will be Medicare obesity coverage from July, the high dose Wegovy launch and competitive dynamics from Eli Lilly's obesity pill launch. Shares fall 2.2%. (dominic.chopping@wsj.com)

(END) Dow Jones Newswires

March 23, 2026 07:02 ET (11:02 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2621200777?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-23 19:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621200777","market":"other","top_or_hot":-1,"title":"Novo Nordisk's Weight-Loss Pill Continues to Impress -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1102 GMT - <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s Wegovy weight-loss pill launch continues to impress, UBS analyst Matthew Weston writes. Latest data show there were 89,279 total prescriptions for the Wegovy pill in its tenth week of launch, up 10% on the week, UBS says. There is also no material evidence that the pill is taking market share from the injectable market, it adds. The bank says sales volumes have risen due to the lower price point compared with the Wegovy injection, which is a positive as the company's guidance assumed more limited volume growth for the injectable product amid competition from the pill. Focus points later in the year will be Medicare obesity coverage from July, the high dose Wegovy launch and competitive dynamics from Eli Lilly's obesity pill launch. Shares fall 2.2%. (dominic.chopping@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 23, 2026 07:02 ET (11:02 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk's Weight-Loss Pill Continues to Impress -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk's Weight-Loss Pill Continues to Impress -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-23 19:02</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1102 GMT - <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s Wegovy weight-loss pill launch continues to impress, UBS analyst Matthew Weston writes. Latest data show there were 89,279 total prescriptions for the Wegovy pill in its tenth week of launch, up 10% on the week, UBS says. There is also no material evidence that the pill is taking market share from the injectable market, it adds. The bank says sales volumes have risen due to the lower price point compared with the Wegovy injection, which is a positive as the company's guidance assumed more limited volume growth for the injectable product amid competition from the pill. Focus points later in the year will be Medicare obesity coverage from July, the high dose Wegovy launch and competitive dynamics from Eli Lilly's obesity pill launch. Shares fall 2.2%. (dominic.chopping@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 23, 2026 07:02 ET (11:02 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2621200777","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621200777","pubTimestamp":1774263720,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1102 GMT - Novo Nordisk's Wegovy weight-loss pill launch continues to impress, UBS analyst Matthew Weston writes. Latest data show there were 89,279 total prescriptions for the Wegovy pill in its tenth week of launch, up 10% on the week, UBS says. There is also no material evidence that the pill is taking market share from the injectable market, it adds. The bank says sales volumes have risen due to the lower price point compared with the Wegovy injection, which is a positive as the company's guidance assumed more limited volume growth for the injectable product amid competition from the pill. Focus points later in the year will be Medicare obesity coverage from July, the high dose Wegovy launch and competitive dynamics from Eli Lilly's obesity pill launch. Shares fall 2.2%. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","NVOH":"Novo Nordisk A/S B Shares ADRhedged","BK4585":"ETF&股票定投概念","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4532":"文艺复兴科技持仓","NVOX":"2倍做多NVO ETF-Defiance","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","NVO":"诺和诺德","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4599":"减肥药","BK4007":"制药","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1"},"translate_title":"诺和诺德的减肥药继续给人留下深刻印象——市场讨论","themeId":"8603dabb40994e59ac78c04c930c0d49","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1.95,"NVOX":0.6,"NVOH":0.6},"content_text":"1102 GMT - Novo Nordisk's Wegovy weight-loss pill launch continues to impress, UBS analyst Matthew Weston writes. Latest data show there were 89,279 total prescriptions for the Wegovy pill in its tenth week of launch, up 10% on the week, UBS says. There is also no material evidence that the pill is taking market share from the injectable market, it adds. The bank says sales volumes have risen due to the lower price point compared with the Wegovy injection, which is a positive as the company's guidance assumed more limited volume growth for the injectable product amid competition from the pill. Focus points later in the year will be Medicare obesity coverage from July, the high dose Wegovy launch and competitive dynamics from Eli Lilly's obesity pill launch. Shares fall 2.2%. (dominic.chopping@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 23, 2026 07:02 ET (11:02 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621200777","isCrawlerRequest":true}